Drug intelligence / Profile preview

docetaxel-alpha-pinene conjugate

Development stage: Preclinical
Lead developer: Sun Yat-sen University
Modality: Small Molecules
Administration: Intravenous

Overview

DTX-PIN is an experimental ligand-drug conjugate (LDC) consisting of the taxane chemotherapy agent docetaxel covalently linked to alpha-pinene. It is specifically designed to target prostate cancer cells that overexpress odorant-binding protein 2A (OBP2A), a protein secreted by tumors undergoing androgen deprivation therapy (ADT). OBP2A facilitates the capture of survival factors like CXCL15/IL-8, promoting the transition to castration-resistant prostate cancer (CRPC). By utilizing alpha-pinene as a targeting ligand, DTX-PIN selectively delivers docetaxel to the tumor microenvironment, where it inhibits microtubule depolymerization, leading to cell cycle arrest and apoptosis. This targeted delivery mechanism aims to enhance the efficacy of docetaxel in CRPC while minimizing systemic side effects.

Other names: alpha-pinene-conjugated docetaxel

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on docetaxel-alpha-pinene conjugate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel-alpha-pinene conjugate.

Explore the full profile